SequelSEC

Advanced Biomed Inc. ADVB

Services-Medical Laboratories · CIK 0001941029 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-03-31
Operating income
Unavailable
Fiscal year ended 2026-03-31
Free cash flow
-$241.04K
Fiscal year ended 2026-03-31

Advanced Biomed Inc. (ADVB) reported net income of -$488.94K for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Advanced Biomed Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

Advanced Biomed Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net income-$488.94K$6.86M-$386.90K-$701.61K-$1.38M-$907.90K-$265.58K-$809.39K-$1.06M-$145.34K
Research & development$243.23K$186.33K$235.99K$309.72K$219.97K$212.40K$181.70K$209.11K$313.51K$188.39K
Weighted-average diluted sharesshares 1.28Mshares 21.64Mshares 21.64MUnavailableshares 1.02Mshares 20.00Mshares 20.00MUnavailableshares 20.00Mshares 20.00M
Pretax income-$488.94K$7.00M-$386.90K-$1.50M-$1.20M-$579.49K-$265.58K-$809.39K-$1.06M-$145.34K
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.38$0.31$-0.02Unavailable$-1.35$-0.05$-0.01Unavailable$-0.05$-0.01
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$276.61K$210.31K$287.92K$1.64M$347.54K$67.67K$338.32K$495.50K$431.90K$462.92K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Advanced Biomed Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$10.65M$10.85M$6.24M$13.72M$8.29M$4.50MUnavailable$4.46MUnavailableUnavailable
Current assets$10.53M$10.73M$5.84M$13.24M$7.73M$3.14MUnavailable$3.05MUnavailableUnavailable
Total liabilities$1.44M$1.37M$3.24M$10.24M$4.16M$3.89MUnavailable$2.80MUnavailableUnavailable
Current liabilities$1.43M$1.25M$3.04M$10.09M$4.11M$3.83MUnavailable$2.73MUnavailableUnavailable
Total equity incl. NCI$9.21M$9.48M$3.00M$3.48M$4.13M$619.03K$1.09M$1.66M-$497.80K$196.84K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$377.26K$369.29K$641.59K$358.24K$618.52K$617.86KUnavailable$620.48KUnavailableUnavailable

Cash flow

Advanced Biomed Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Operating cash flow-$239.78K-$513.56K-$610.34K-$1.54M-$3.41M-$841.84K-$29.68K-$475.83K-$1.07MUnavailable
Capital expenditures$1.26K$12.91K$1.77K$20.15K$2.22K-$10.69K$19.98K$53.26K-$26.70KUnavailable
Investing cash flow-$1.26K-$12.91K-$1.77K-$20.15K-$2.22K$10.69K-$19.98K-$53.26K$26.70KUnavailable
Financing cash flow$268.28K$315.48K$447.46K-$765.47K$5.90M$408.29K$392.52K$323.54K$562.20KUnavailable
Net change in cash-$1.97K-$45.93K-$247.40K-$2.28M$2.53M$10.24K$39.02K-$55.73K-$112.92KUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$9.33K-$12.86K$47.99K$275.86K$22.51K-$56.76K$102.22K$153.91K$83.02KUnavailable

Derived

Advanced Biomed Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Free cash flow-$241.04K-$526.46K-$612.11K-$1.56M-$3.41MUnavailable-$49.66K-$529.08KUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio7.38x8.56x1.92x1.31x1.88x0.82xUnavailable1.12xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ADVB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-K · Filed 2025-10-08View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-Q · Filed 2025-04-15View SEC filing

Companies in the same industry

ACON AMS BDSX BGLC BLLN CAI CDNA CELC CFOR CSTL DGX FCHS

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.